All In Biotech

NDA 214783 · Sanofi-Aventis

Rezurock

Belumosudil Mesylate · Oral

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Jul 16, 2021: To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 16, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

40

3 Phase 3, 12 recruiting

FAERS reports

3,361

1,679 serious, 303 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2026.

REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. ( 1 )

Mechanism: Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 with IC 50 values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro -human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, in vitro . In vivo , belumosudil demonstrated activity in animal models of chronic GVHD.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 16, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
  • REZUROCK · BELUMOSUDIL MESYLATE EQ 200MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Belumosudil" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication484
  • inappropriate schedule of product administration466
  • fatigue273
  • off label use240
  • drug ineffective179
  • pneumonia178
  • death169
  • nausea165
  • product dose omission issue160
  • diarrhoea151
  • hospitalisation146
  • condition aggravated145

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
202173
2022898
2023290
2024781
2025732
2026586

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rezurock (Belumosudil Mesylate)

2024 spending

$243M

Beneficiaries

1,371

10,182 claims

Per beneficiary

$177,193

$579.03 per unit

View as table
YearSpending
2020$0
2021$21,356,248
2022$100,434,804
2023$146,107,630
2024$242,932,266

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.